Regorafenib Combined With TAS-102 Versus Regorafenib Monotherapy in Third or Later Line Therapy of mCRC

NCT05970705 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

101

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Colorectal Cancer

Interventions

DRUG: Regorafenib
DRUG: Trifluridine/Tipiracil

Sponsor

Fudan University